{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T07:33:09Z","timestamp":1694935989132},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.clml.2013.11.010","type":"journal-article","created":{"date-parts":[[2013,11,22]],"date-time":"2013-11-22T22:48:42Z","timestamp":1385160522000},"page":"e55-e58","source":"Crossref","is-referenced-by-count":4,"title":["Development of Lymphomas Containing Epstein-Barr Virus After Therapy With Hyper-CVAD Regimen"],"prefix":"10.1016","volume":"14","author":[{"given":"Marlise R.","family":"Luskin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darshan B.","family":"Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariusz A.","family":"Wasik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison W.","family":"Loren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2013.11.010_bib1","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1182\/blood.V81.8.2102.2102","article-title":"Epstein-Barr virus-associated non-Hodgkin's lymphoma in patients infected with the human immunodeficiency virus","volume":"81","author":"Shibata","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.11.010_bib2","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1182\/blood-2008-06-164806","article-title":"Age-related Epstein-Barr virus (EBV)-associated B-cell lymphoproliferative disorders: comparison with EBV-positive classic Hodgkin lymphoma in elderly patients","volume":"113","author":"Asano","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.11.010_bib3","doi-asserted-by":"crossref","first-page":"4726","DOI":"10.1182\/blood-2010-12-323238","article-title":"Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma","volume":"117","author":"Dojcinov","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.11.010_bib4","first-page":"964055","article-title":"Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response","author":"Yang","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.11.010_bib5","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMra032015","article-title":"Persistence of the Epstein-Barr virus and the origins of associated lymphomas","volume":"350","author":"Thorley-Lawson","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2013.11.010_bib6","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1136\/jcp.53.4.248","article-title":"The role of EBV in post-transplant malignancies: a review","volume":"53","author":"Hopwood","year":"2000","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.clml.2013.11.010_bib7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.critrevonc.2005.03.015","article-title":"Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation","volume":"56","author":"Taylor","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clml.2013.11.010_bib8","first-page":"2208","article-title":"Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study","volume":"94","author":"Curtis","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.11.010_bib9","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ccm.2005.06.014","article-title":"Post-transplant lymphoproliferative disorder","volume":"26","author":"Loren","year":"2005","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.clml.2013.11.010_bib10","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.leukres.2005.10.022","article-title":"Fulminant Epstein-Barr virus (EBV)-associated T-cell lymphoproliferative disorder with hemophagocytosis following autologous peripheral blood stem cell transplantation for relapsed angioimmunoblastic T-cell lymphoma","volume":"30","author":"Awaya","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2013.11.010_bib11","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.3892\/ol.2012.670","article-title":"Epstein-Barr virus-associated lymphoproliferative disorder developed following autologous peripheral blood stem cell transplantation for relapsing Hodgkin's lymphoma","volume":"3","author":"Izumiya","year":"2012","journal-title":"Oncol Lett"},{"key":"10.1016\/j.clml.2013.11.010_bib12","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/sj.bmt.1702721","article-title":"Epstein-Barr virus-associated T cell lymphoproliferative disorder following autologous blood stem cell transplantation for relapsed Hodgkin's disease","volume":"26","author":"Yufu","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2013.11.010_bib13","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1097\/00007890-199306000-00040","article-title":"Epstein-Barr virus-associated lymphoproliferative disorder following autologous bone marrow transplantation for non-Hodgkin's lymphoma","volume":"55","author":"Chao","year":"1993","journal-title":"Transplantation"},{"key":"10.1016\/j.clml.2013.11.010_bib14","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/sj.bmt.1701258","article-title":"Epstein-Barr virus-associated lymphoproliferative disorder after autologous bone marrow transplantation: report of two cases","volume":"21","author":"Hauke","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2013.11.010_bib15","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1046\/j.1365-2141.1997.2153034.x","article-title":"Epstein-Barr virus associated B-cell lymphoma after autologous bone marrow transplantation for T-cell acute lymphoblastic leukaemia","volume":"98","author":"Briz","year":"1997","journal-title":"Br J Haemtaol"},{"key":"10.1016\/j.clml.2013.11.010_bib16","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/sj.bmt.1701335","article-title":"A\u00a0case of EBV-associated lymphoproliferative disease following high-dose therapy and CD34-purified autologous peripheral blood progenitor cell transplantation","volume":"22","author":"Peniket","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2013.11.010_bib17","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/sj.bmt.1704402","article-title":"An unexpectedly high incidence of Epstein-Barr virus lymphoproliferative disease after CD34+ selected autologous peripheral blood stem cell transplant in neuroblastoma","volume":"33","author":"Powell","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2013.11.010_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/S1083-8791(03)00228-3","article-title":"Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases","author":"Nash","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2013.11.010_bib19","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/sj.bmt.1704026","article-title":"Epstein-Barr virus-associated B-cell lymphoproliferative disorder in CLL patients after treatment with fludarabine and cyclophosphamide followed by high-dose chemotherapy with autologous stem cell transplantation","volume":"31","author":"Jindra","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2013.11.010_bib20","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1182\/blood-2003-12-4428","article-title":"Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.11.010_bib21","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1002\/cncr.20668","article-title":"Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"101","author":"Kantarjian","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2013.11.010_bib22","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"issue":"suppl 2","key":"10.1016\/j.clml.2013.11.010_bib23","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.3816\/CLM.2007.s.034","article-title":"Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas","volume":"8","author":"Fayad","year":"2007","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.clml.2013.11.010_bib24","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00277-008-0488-6","article-title":"Prolonged haematological toxicity from the hyper-CVAD regimen: manifestations, frequency, and natural history in a cohort of 125 consecutive patients","volume":"87","author":"Gill","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2013.11.010_bib25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/cncr.24005","article-title":"Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens","volume":"115","author":"Verma","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2013.11.010_bib26","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s11864-013-0231-y","article-title":"EBV-related lymphomas: new approaches to treatment","volume":"14","author":"Kanakry","year":"2013","journal-title":"Curr Treat Options Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265013004941?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265013004941?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T13:30:14Z","timestamp":1597066214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265013004941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S2152265013004941"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2013.11.010","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]}}}